BRAIN Biotech AG (HAM:BNN) Cyclically Adjusted FCF per Share: €-0.28 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HAM:BNN BRAIN Biotech AG HAM:BNN
68 GF Score
Price €2.74
GF Value €2.52
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is BRAIN Biotech AG Cyclically Adjusted FCF per Share?

BRAIN Biotech AG HAM:BNN -1.44% 68 Cyclically Adjusted FCF per Share is €-0.28 as of Mar. 2026. GuruFocus rates HAM:BNN with a GF Score™ of 68/100 and a GF Value™ of €2.52 (Fairly Valued). The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

BRAIN Biotech AG's adjusted free cash flow per share for the three months ended in Mar. 2026 was €0.034. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €-0.28 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2026-07-20), BRAIN Biotech AG's current stock price is €2.74. BRAIN Biotech AG's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was €-0.28. BRAIN Biotech AG's Cyclically Adjusted Price-to-FCF of today is .


BRAIN Biotech AG  (HAM:BNN) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


BRAIN Biotech AG Cyclically Adjusted FCF per Share Related Terms


BRAIN Biotech AG Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for BRAIN Biotech AG's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BRAIN Biotech AG Cyclically Adjusted FCF per Share Chart

BRAIN Biotech AG Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 -0.32 -0.32

BRAIN Biotech AG Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.33 -0.30 -0.32 -0.30 -0.28

HAM:BNN vs LIN, SHW, ECL: Cyclically Adjusted FCF per Share Comparison

For the Specialty Chemicals subindustry, BRAIN Biotech AG's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BRAIN Biotech AG Cyclically Adjusted Price-to-FCF vs Chemicals Industry

For the Chemicals industry and Basic Materials sector, BRAIN Biotech AG's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where BRAIN Biotech AG's Cyclically Adjusted Price-to-FCF falls into.


HAM:BNN
68GF Score
BRAIN Biotech AG HAM:BNN
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BRAIN Biotech AG Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, BRAIN Biotech AG's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.034/131.2583*131.2583
=0.034

Current CPI (Mar. 2026) = 131.2583.

BRAIN Biotech AG Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -0.148 100.717 -0.193
201609 -0.106 101.017 -0.138
201612 -0.004 101.217 -0.005
201703 -0.133 101.417 -0.172
201706 -0.119 102.117 -0.153
201709 -0.093 102.717 -0.119
201712 0.075 102.617 0.096
201803 -0.231 102.917 -0.295
201806 -0.188 104.017 -0.237
201809 0.044 104.718 0.055
201812 -0.008 104.217 -0.010
201903 -0.152 104.217 -0.191
201906 -0.111 105.718 -0.138
201909 0.084 106.018 0.104
201912 -0.032 105.818 -0.040
202003 -0.198 105.718 -0.246
202006 -0.087 106.618 -0.107
202009 0.049 105.818 0.061
202012 -0.107 105.518 -0.133
202103 -0.102 107.518 -0.125
202106 0.058 108.486 0.070
202109 -0.045 109.435 -0.054
202112 -0.009 110.384 -0.011
202203 -0.040 113.968 -0.046
202206 0.001 115.760 0.001
202209 -0.021 118.818 -0.023
202212 -0.094 119.345 -0.103
202303 -0.161 122.402 -0.173
202306 0.049 123.140 0.052
202309 0.012 124.195 0.013
202312 -0.121 123.773 -0.128
202403 -0.025 125.038 -0.026
202406 0.024 125.882 0.025
202409 -0.042 126.198 -0.044
202412 -0.153 127.041 -0.158
202503 -0.074 127.779 -0.076
202506 -0.084 128.412 -0.086
202509 -0.112 129.255 -0.114
202512 -0.094 129.361 -0.095
202603 0.034 131.258 0.034

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of €-0.28 mean?
BRAIN Biotech AG (HAM:BNN) has a Cyclically Adjusted FCF per Share of €-0.28 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on BRAIN Biotech AG and its competitors.
Is BRAIN Biotech AG's Cyclically Adjusted FCF per Share too high?
BRAIN Biotech AG's current Cyclically Adjusted FCF per Share is €-0.28. Overall, BRAIN Biotech AG has a GF Score™ of 68/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does BRAIN Biotech AG's Cyclically Adjusted FCF per Share compare to LIN and SHW?
BRAIN Biotech AG's Cyclically Adjusted FCF per Share of €-0.28 can be compared against companies in the Chemicals industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Chemicals company?
A good Cyclically Adjusted FCF per Share depends on the Chemicals industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on BRAIN Biotech AG and its competitors. BRAIN Biotech AG's current Cyclically Adjusted FCF per Share is €-0.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BRAIN Biotech AG stock overvalued right now?
Based on GuruFocus' analysis, BRAIN Biotech AG (HAM:BNN) is currently considered Fairly Valued. The stock's GF Value™ is €2.52, compared to a current price of €2.74 — trading 8.7% above its estimated fair value. The current Cyclically Adjusted FCF per Share is €-0.28. BRAIN Biotech AG's overall GF Score™ is 68/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For BRAIN Biotech AG (HAM:BNN), the current Cyclically Adjusted FCF per Share is €-0.28 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BRAIN Biotech AG (HAM:BNN) Overvalued in 2026?

Based on GuruFocus' analysis, BRAIN Biotech AG stock appears to be overvalued. The current stock price of €2.74 is trading 8.7% above its estimated GF Value™ of €2.52. GuruFocus considers BRAIN Biotech AG to be Fairly Valued.

Key valuation signals for HAM:BNN:

  • Cyclically Adjusted FCF per Share: €-0.28
  • GF Value™: €2.52 vs. price of €2.74 (8.7% above fair value)
  • GF Score™: 68/100 with 2 warning signs

No single metric tells the full story. See the HAM:BNN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


BRAIN Biotech AG Business Description

Other Exchanges 0RFI:UKBNN:Germany
Address Darmstadter Strasse 34-36, Zwingenberg, BW, DEU, 64673
BRAIN Biotech AG is an industrial biotechnology specialist focused on enzyme technology, microbial production strains, and bioprocess design to enable bio-based innovations. The Group conducts research, development, and production for client specifications and its own product portfolio, supporting customers in the food and beverage, chemical, and life sciences industries with solutions that enhance productivity, efficiency, and sustainability. Its operations are organized into two segments: BRAIN Biocatalysts, which develops, produces, and distributes specialty enzymes, microorganisms, and ingredients and generates the majority of revenue, and BRAIN BioIncubator, which focuses on development projects. The company operates in Germany and other countries.
68GF Score

Get the complete analysis for HAM:BNN

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.74
Price
€2.52
GF Value